Diagnostic and Prognostic Roles of IRAK1 in Hepatocellular Carcinoma Tissues: an Analysis of Immunohistochemistry and RNA-sequencing Data from the Cancer Genome Atlas

Overview

Journal Onco Targets Ther

Publisher Dove Medical Press

Specialty Oncology

Date 2017 Mar 31

PMID 28356759

Citations 20

Authors

Zhi-Hua Ye

Li Gao

Dong-Yue Wen

Yun He

Yu-Yan Pang

Gang Chen

Affiliations

Soon will be listed here.

Abstract

Background: IRAK1 has been repoted to play an essential role in the development of multiple cancers. However, the clinical significance of IRAK1 in hepatocellular carcinoma (HCC) and the underlying molecular mechanism remain unclear. Therefore, we aimed to investigate the role of IRAK1 in the pathogenesis of HCC in this study.

Materials And Methods: HCC tissues and para-carcinoma tissues were collected for immunohistochemistry (IHC) analysis to evaluate IRAK1 expression. Data of IRAK1 expression were downloaded from the cancer genome atlas (TCGA) for analyzing the clinical significance of IRAK1. Receiver operating characteristic (ROC) curve and survival analyses were carried out to assess the diagnostic and prognostic significance of IRAK1 in IHC and TCGA data. Additionally, we investigated the alteration of gene in HCC from cBioPortal to generate a network of the interaction between IRAK1 and the neighboring genes. The influence of gene alteration on the prognosis of HCC patients was evaluated by survival analysis.

Results: Analysis of both IHC and TCGA data revealed a significant upregulation of IRAK1 in HCC tissues. The IHC analysis revealed there was an increasing trend in IRAK1 expression among normal liver tissues, liver cirrhosis tissues, para-carcinoma tissues and HCC tissues. The ROC curves for IHC and TCGA data demonstrated that IRAK1 exhibited a significant diagnostic value for HCC. Moreover, IRAK1 expression was observed to be associated with tumor size, metastasis and T-stage. The survival analysis indicated that the upregulation of IRAK1 predicted a worse overall survival of HCC. Additionally, data from cBioPortal confirmed that 29% of HCC tissues possessed an alteration of the gene.

Conclusion: IRAK1 may act as an oncogene in the development of HCC with its overexpression in HCC. Moreover, IRAK1 might serve as a promising diagnostic and therapeutic target for HCC.

Citing Articles

Enzymatic TET-1 inhibition highlights different epigenetic behaviours of IL-1β and TNFα in tumour progression of OS cell lines.

Bellavia D, Caruccio S, Caradonna F, Costa V, Urzi O, Raimondi L Clin Epigenetics. 2024; 16(1):136.

PMID: 39358792 PMC: 11448002. DOI: 10.1186/s13148-024-01745-4.

Constructing a prognostic model for hepatocellular carcinoma based on bioinformatics analysis of inflammation-related genes.

Li Y, Fang Y, Li D, Wu J, Huang Z, Liao X Front Med (Lausanne). 2024; 11:1420353.

PMID: 39055701 PMC: 11269197. DOI: 10.3389/fmed.2024.1420353.

TGFβR1 inhibition drives hepatocellular carcinoma proliferation through induction of toll-like-receptor signalling.

Mohamed F, Dewidar B, Lin T, Ebert M, Dooley S, Meindl-Beinker N Int J Exp Pathol. 2024; 105(2):64-74.

PMID: 38328944 PMC: 10951419. DOI: 10.1111/iep.12501.

The Molecular Basis and Clinical Consequences of Chronic Inflammation in Prostatic Diseases: Prostatitis, Benign Prostatic Hyperplasia, and Prostate Cancer.

Oseni S, Naar C, Pavlovic M, Asghar W, Hartmann J, Fields G Cancers (Basel). 2023; 15(12).

PMID: 37370720 PMC: 10296711. DOI: 10.3390/cancers15123110.

IRAK2, an Immune and Radiation-Response Gene, Correlates with Advanced Disease Features but Predicts Higher Post-Irradiation Local Control in Non-Metastatic and Resected Oral Cancer Patients.

Yu C, Lin H, Hsieh C, Chan M, Chiou W, Lee M Int J Mol Sci. 2023; 24(8).

PMID: 37108068 PMC: 10138613. DOI: 10.3390/ijms24086903.

References

Rhyasen G, Bolanos L, Fang J, Jerez A, Wunderlich M, Rigolino C . Targeting IRAK1 as a therapeutic approach for myelodysplastic syndrome. Cancer Cell. 2013; 24(1):90-104. PMC: 3711103. DOI: 10.1016/j.ccr.2013.05.006. View

Wesche H, Henzel W, Shillinglaw W, Li S, Cao Z . Pillars article: MyD88: an adapter that recruits IRAK to the IL-1 receptor complex. Immunity. 1997. 7: 837-847. J Immunol. 2012; 190(1):5-15. View

Scheeren F, Kuo A, van Weele L, Cai S, Glykofridis I, Sikandar S . A cell-intrinsic role for TLR2-MYD88 in intestinal and breast epithelia and oncogenesis. Nat Cell Biol. 2014; 16(12):1238-48. DOI: 10.1038/ncb3058. View

Janssens S, Beyaert R . Functional diversity and regulation of different interleukin-1 receptor-associated kinase (IRAK) family members. Mol Cell. 2003; 11(2):293-302. DOI: 10.1016/s1097-2765(03)00053-4. View

ONeill L, Golenbock D, Bowie A . The history of Toll-like receptors - redefining innate immunity. Nat Rev Immunol. 2013; 13(6):453-60. DOI: 10.1038/nri3446. View

Cao Z, Henzel W, Gao X . IRAK: a kinase associated with the interleukin-1 receptor. Science. 1996; 271(5252):1128-31. DOI: 10.1126/science.271.5252.1128. View

Li Z, Younger K, Gartenhaus R, Mary Joseph A, Hu F, Baer M . Inhibition of IRAK1/4 sensitizes T cell acute lymphoblastic leukemia to chemotherapies. J Clin Invest. 2015; 125(3):1081-97. PMC: 4362243. DOI: 10.1172/JCI75821. View

Siegel R, Miller K, Jemal A . Cancer statistics, 2016. CA Cancer J Clin. 2016; 66(1):7-30. DOI: 10.3322/caac.21332. View

Gao J, Aksoy B, Dogrusoz U, Dresdner G, Gross B, Sumer S . Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013; 6(269):pl1. PMC: 4160307. DOI: 10.1126/scisignal.2004088. View

10.

Li J, Liang L, Liu Y, Luo Y, Liang X, Luo D . Clinicopathological significance of STAT4 in hepatocellular carcinoma and its effect on cell growth and apoptosis. Onco Targets Ther. 2016; 9:1721-34. PMC: 4807935. DOI: 10.2147/OTT.S100040. View

11.

Li N, Jiang J, Fu J, Yu T, Wang B, Qin W . Targeting interleukin-1 receptor-associated kinase 1 for human hepatocellular carcinoma. J Exp Clin Cancer Res. 2016; 35(1):140. PMC: 5020546. DOI: 10.1186/s13046-016-0413-0. View

12.

Zhang X, Dang Y, Li P, Rong M, Chen G . Expression of IRAK1 in lung cancer tissues and its clinicopathological significance: a microarray study. Int J Clin Exp Pathol. 2015; 7(11):8096-104. PMC: 4270603. View

13.

Zhang G, Ghosh S . Toll-like receptor-mediated NF-kappaB activation: a phylogenetically conserved paradigm in innate immunity. J Clin Invest. 2001; 107(1):13-9. PMC: 198554. DOI: 10.1172/JCI11837. View

14.

Li J, Luo J, Lu J, Liang X, Luo Y, Liu Y . Relationship between TRAF6 and deterioration of HCC: an immunohistochemical and in vitro study. Cancer Cell Int. 2016; 16:76. PMC: 5041287. DOI: 10.1186/s12935-016-0352-z. View

15.

Srivastava R, Geng D, Liu Y, Zheng L, Li Z, Joseph M . Augmentation of therapeutic responses in melanoma by inhibition of IRAK-1,-4. Cancer Res. 2012; 72(23):6209-16. PMC: 3677596. DOI: 10.1158/0008-5472.CAN-12-0337. View

16.

Flannery S, Bowie A . The interleukin-1 receptor-associated kinases: critical regulators of innate immune signalling. Biochem Pharmacol. 2010; 80(12):1981-91. DOI: 10.1016/j.bcp.2010.06.020. View

17.

White D, Thrift A, Kanwal F, Davila J, El-Serag H . Incidence of Hepatocellular Carcinoma in All 50 United States, From 2000 Through 2012. Gastroenterology. 2016; 152(4):812-820.e5. PMC: 5346030. DOI: 10.1053/j.gastro.2016.11.020. View

18.

Rakoff-Nahoum S, Medzhitov R . Toll-like receptors and cancer. Nat Rev Cancer. 2008; 9(1):57-63. DOI: 10.1038/nrc2541. View

19.

Balogh J, Victor 3rd D, Asham E, Burroughs S, Boktour M, Saharia A . Hepatocellular carcinoma: a review. J Hepatocell Carcinoma. 2016; 3:41-53. PMC: 5063561. DOI: 10.2147/JHC.S61146. View

20.

Wee Z, Yatim S, Kohlbauer V, Feng M, Goh J, Bao Y . IRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxel. Nat Commun. 2015; 6:8746. PMC: 4640083. DOI: 10.1038/ncomms9746. View